natgillin/translations-raw huggingface dataset:
In a clinical study (D-Pan-H5N1-009), children aged 3 to 5 and 6 to 9 years old received two doses of either a full (0.5 ml) or a half dose (0.25 ml) of an AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1) at 0 and 21 days.
V klinični študiji (D-Pan-H5N1-009) so otroci, stari od 3 do 5 in od 6 do 9 let, dvakrat dobili bodisi polni odmerek (0,5 ml) bodisi polovični odmerek (0,25 ml) cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA pridobljenega iz A/Vietnam/1194/2004 (H5N1) na dan 0 in dan 21.
In a clinical study (D-Pan-H5N1-009), children aged 3 to 5 and 6 to 9 years old received two doses of either a full (0.5 ml) or a half dose (0.25 ml) of an AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1) at 0 and 21 days.
V klinični študiji (D-Pan-H5N1-009) so otroci, stari od 3 do 5 in od 6 do 9 let, dvakrat dobili bodisi polni odmerek (0,5 ml) bodisi polovični odmerek (0,25 ml) cepiva z adjuvansom AS03, z vsebnostjo 3,75 µg HA, pridobljenega iz A/Vietnam/1194/2004 (H5N1) na dan 0 in dan 21.
In a clinical study (D-Pan-H5N1-009, -023), children aged 3 to 5 and 6 to 9 years old received two doses of either a full (0.5 ml) or a half dose (0.25 ml) of an AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1) at 0 and 21 days.
V klinični študiji (D-Pan-H5N1-009, -023) so otroci, stari od 3 do 5 in od 6 do 9 let, dvakrat dobili bodisi polni odmerek (0,5 ml) bodisi polovični odmerek (0,25 ml) cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA iz A/Vietnam/1194/2004 (H5N1) na dan 0 in dan 21.
In a clinical study (Q-Pan-H5N1-010), a booster dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Turkey/Turkey/1/2005 was given 15 months after primary vaccination.
V klinični študiji (Q-Pan-H5N1-010) je bil 15 mesecev po primarnem cepljenju uporabljen obnovitveni odmerek cepiva z adjuvansom AS03 z vsebnostjo 3,75 µg HA iz A/Turkey/Turkey/1/2005.
In a clinical study conducted in subjects over 40 years of age, the seropositivity rate for anti-HAV antibodies and seroprotection rate against hepatitis B of Twinrix Adult following a 0, 1, 6 months schedule were compared with the seropositivity and seroprotection rates of monovalent hepatitis A and B vaccines when administered in opposite arms.
V klinični študiji pri osebah, starejših od 40 let, so primerjali stopnjo seropozitivnosti na anti-HAV protitelesa in protitelesa proti hepatitisu B po dajanju cepiva Twinrix za odrasle v standardni shemi (0- 1-6) v primerjavi s seropozitivnostjo in stopnjo serumske zaščite po monovalentnih cepivih hepatitisa A in B po dajanju v nasprotno roko.
In a clinical study for the treatment of acute gynaecologic infections, in adults, 26 % of evaluable patients treated with ertapenem had severe disease (defined as temperature  39C and/or bacteraemia); ten patients had bacteraemia.
V klinični študiji zdravljenja akutnih ginekoloških okužb pri odraslih je imelo 26 % bolnic, ki jih je bilo mogoče oceniti in ki so se zdravile z ertapenemom, hudo bolezen (opredeljeno s telesno temperaturo  39 C in/ali z bakteriemijo); deset bolnic je imelo bakteriemijo.
In a clinical study in 32 adult patients with severe haemophilia A, the median consumption of Nuwiq for prophylaxis was 468.7 IU/kg/month.
V klinični študiji 32 odraslih bolnikov s hudo hemofilijo A je bila mediana porabe zdravila Nuwiq za preventivo 468,7 i.e./kg/mesec.
In a clinical study in adults aged 18 to 59 years (N=265) and in older people aged 60 years and above (N=270) after vaccination with the A/Vietnam/1203/2004 strain vaccine, the rate of subjects with cross-neutralising antibodies as measured by MN (titre ≥ 20) was as follows:
V klinični študiji pri odraslih, starih od 18 do 59 let (N=265), in starejših osebah, starih 60 let in več (N=270) je bil po cepljenju s cepivom iz seva A/Vietnam/1203/2004 odstotek oseb z navzkrižnimi nevtralizacijskimi protitelesi, izmerjen z mikronevtralizacijo (titer ≥ 20), naslednji:
In a clinical study in Asian patients from China and South-Korea, increased blood ‘bilirubin’ levels were reported in more than 1 in 10 people (very common).
V klinični študiji pri bolnikih azijskega porekla s Kitajske in Južne Koreje so poročali o zvečani koncentraciji bilirubina v krvi pri več kot 1 od 10 bolnikov (zelo pogosto).
In a clinical study in healthy children 6 months to 35 months of age (stratified in ranges from 6 to 11, 12 to 23 and 24-35 months of age) the anti-HA antibody responses 21 days after a first and a second half adult dose (i.e.
V klinični študiji pri zdravih otrocih, starih od 6 do 35 mesecev (razdeljenih v skupine od 6 do 11, 12 do 23 in 24 do 35 mesecev) so bili odzivi anti-HA protiteles 21 dni po prvem in drugem polovičnem odmerku za odrasle (tj.
In a clinical study in healthy volunteers, cimetidine, an inhibitor of organic cation transport which is thought to contribute to the renal excretion of glycopyrronium, increased total exposure (AUC) to glycopyrronium by 22% and decreased renal clearance by 23%.
V klinični študiji z zdravimi prostovoljci je cimetidin, zaviralec transporta organskih kationov, ki je domnevno vpleten v izločanje glikopironija preko ledvic, povečal skupno izpostavljenost (AUC) glikopironiju za 22 %, ledvični očistek pa zmanjšal za 23 %.
In a clinical study in healthy volunteers, steady-state dosing with ambrisentan 10 mg once daily did not significantly affect the single-dose pharmacokinetics of the ethinyl estradiol and norethindrone components of a combined oral contraceptive (see section 5.2).
V kliničnih študijah pri zdravih prostovoljcih odmerjanje ambrisentana 10 mg enkrat na dan v stanju dinamičnega ravnovesja ni pomembno vplivalo na farmakokinetiko enkratnega odmerka etinilestradiolske in noretindronske sestavine kombiniranega peroralnega kontraceptiva (glejte poglavje 5.2).
In a clinical study in healthy volunteers, tafamidis meglumine did not induce or inhibit the cytochrome P450 enzyme CYP3A4.
V klinični študiji pri zdravih prostovoljcih tafamidis meglumin ni niti induciral niti zaviral encima citokroma P450 CYP3A4.
In a clinical study in patients with hepatic impairment (degree of impairment based on subject’s AST and total bilirubin levels) following multiple doses of vismodegib, it was shown that in patients with mild (NCI-ODWG criteria, n=8), moderate (NCI-ODWG criteria, n=6), and severe (NCI-ODWG criteria, n=3) hepatic impairment, the pharmacokinetic profile of vismodegib was comparable to that of subjects with normal hepatic function (n=9) (see section 4.2).
V klinični študiji pri bolnikih z jetrno okvaro (stopnja okvare je temeljila na vrednosti posameznikove aspartat aminotransferaze (AST) in celokupne ravni bilirubina) so imeli po večkratnih odmerkih vismodegiba bolniki z blago (merila NCI-ODWG, n = 8), zmerno (merila NCI-ODWG, n = 6) in hudo (merila NCI-ODWG, n = 3) jetrno okvaro farmakokinetični profil vismodegiba primerljiv s profilom vismodegiba pri posameznikih z normalnim delovanjem jeter (n = 9) (glejte poglavje 4.2).
In a clinical study in patients with metastatic CRPC, Xtandi (160 mg once daily) had no clinically relevant effect on the pharmacokinetics of intravenously administered docetaxel (75 mg/m2 by infusion every 3 weeks).
V klinični študiji pri bolnikih z metastatskim CRPC zdravilo Xtandi (160 mg enkrat na dan) ni imelo nobenega klinično pomembnega učinka na farmakokinetiko intravensko uporabljenega docetaksela (75 mg/m2 z infuzijo vsake 3 tedne).
In a clinical study in patients without advanced cancer, 19% of patients with severe renal impairment (creatinine clearance < 30 ml/min) and 63% of patients receiving dialysis developed hypocalcaemia despite calcium supplementation.
V klinični študiji pri bolnikih brez napredovalega raka se je hipokalciemija kljub dodajanju kalcija pojavila pri 19 % bolnikov s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) in pri 63 % bolnikov na dializi.
In a clinical study in which children aged 3 to 9 years old received a half adult dose (0.25 ml) of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/California/7/2009 (H1N1)v-like the anti-HA antibody responses 21 days after a first dose were as follows:
V klinični študiji, v kateri so otroci, stari od 3 do 9 let dobili polovični odmerek (0,25 ml) cepiva z adjuvansom AS03 in vsebnostjo 3,75 µg HA pridobljenega iz A/California/7/2009 (H1N1)v- podobnega seva, so bili odzivi anti-HA protiteles 21 dni po prvem odmerku naslednji:
In a clinical study in which some of the vaccinees received a booster dose of Infanrix hexa concomitantly with measles-mumps-rubella-varicella (MMRV) vaccine, fever  38.0°C was reported in 76.6% of children receiving MMRV vaccine and Infanrix hexa at the same time, as compared to 48% of children receiving Infanrix hexa alone and 74.7% of children receiving MMRV vaccine alone.
V klinični študiji, v kateri so nekateri cepljeni otroci dobili obnovitveni odmerek cepiva Infanrix hexa sočasno s cepivom MMRV (cepivo proti ošpicam-mumpsu-rdečkam-noricam), so zvišano telesno temperaturo ≥ 38,0 °C zabeležili pri 76,6 % otrok, ki so hkrati prejeli cepivi MMRV in Infanrix hexa; med uporabo cepiva Infanrix hexa samega je bil ta delež 48 % in med uporabo cepiva MMRV samega 74,7 %.
In a clinical study in young healthy subjects, no relevant effect of memantine on the pharmacokinetics of galantamine was observed.
V klinični raziskavi pri mladih zdravih posameznikih niso opazili pomembnega vpliva memantina na farmakokinetiko galantamina.
In a clinical study including 43 adult and paediatric patients (36 patients aged 8 months to < 18 years) with severe CAPS (NOMID/CINCA and MWS), a clinical response to anakinra was seen within 10 days after initiation of treatment in all patients and was sustained for up to 5 years with the continued administration of Kineret.
V klinični študiji, ki je vključevala 43 odraslih in pediatričnih bolnikov (36 bolnikov, starih od 8 mesecev do <18 let) s hudimi CAPS (NOMID/CINCA in MWS), so pri vseh bolnikih v 10 dneh po uvedbi zdravljenja opazili klinični odziv na anakinro, ki se je obdržal do 5 let pri nadaljnjem dajanju zdravila Kineret.
In a clinical study investigating the interaction of rifampicin 600 mg once daily and saquinavir 1000 mg with ritonavir 100 mg twice daily in healthy volunteers, severe hepatocellular toxicity with transaminase elevations up to > 20-fold the upper limit of normal after 1 to 5 days of co-administration was noted.
V klinični študiji, s katero so pri zdravih prostovoljcih raziskali medsebojno delovanje 600 mg rifampicina enkrat na dan ter 1000 mg sakvinavirja s 100 mg ritonavirja dvakrat na dan, so po 1 do 5 dneh sočasne uporabe zabeležili hude toksične učinke na jetrne celice z zvišanjem transaminaz do > 20-kratno zgornjo mejo normalnih vrednosti.
In a clinical study investigating the survival time in dogs with congestive heart failure, there was a 65% reduction in the relative risk of mortality at 15 months in dogs treated with spironolactone in combination with standard therapy compared to dogs treated with standard therapy alone. (Mortality was classified as death or euthanasia due to heart failure).
Pri kliničnih testiranjih psov s kronično srčno odpovedjo, so rezultati pokazali 65% zmanjšanje rizičnosti smrtnosti pri 15 mesečnih psih, ki so bili tretirani s spironolaktonom v kombinaciji s standardno terapijo kot pri psih,ki so bili zdravljeni samo s standardno terapijo. ( smrtnost je bila klasificirana kot pogin ali eutanazija zaradi srčne odpovedi. )
In a clinical study investigating the survival time in dogs with congestive heart failure, there was a 65% reduction in the relative risk of mortality at 15 months in dogs treated with spironolactone in combination with standard therapy compared to dogs treated with standard therapy alone. (Mortality was classified as death or euthanasia due to heart failure).
Pri kliničnih testiranjih psov s kronično srčno odpovedjo, so rezultati pokazali 65% zmanjšanje rizičnosti smrtnosti pri 15 mesečnih psih, ki so bili tretirani s spironolaktonom v kombinaciji s standardno terapijo kot pri psih,ki so bili zdravljeni samo s standardno terapijo. ( smrtnost je bila klasificirana kot pogin ali evtanazija zaradi srčne odpovedi. )
In a clinical study of ESRD patients on dialysis, free testosterone levels decreased by a median of 31.3% in the cinacalcet-treated patients and by 16.3% in the placebo-treated patients after 6 months of treatment.
V klinični študiji bolnikov s končno odpovedjo ledvic na dializi se je koncentracija prostega testosterona po 6 mesecih zdravljenja s cinakalcetom znižala za mediano 31,3%, po 6 mesecih uporabe placeba pa za mediano 16,3%.
In a clinical study of ESRD patients on dialysis, free testosterone levels decreased by a median of 31.3% in the Mimpara-treated patients and by 16.3% in the placebo-treated patients after 6 months of treatment.
V klinični študiji bolnikov s končno odpovedjo ledvic na dializi se je koncentracija prostega testosterona po 6 mesecih zdravljenja z zdravilom Mimpara znižala za mediano 31,3 %, po 6 mesecih uporabe placeba pa za mediano 16,3 %.
In a clinical study of NSTEMI patients (the ACCOAST study), where patients were scheduled to undergo coronary angiography within 2 to 48 hours after randomization, patients given a 30 mg loading dose on average 4 hours prior to coronary angiography followed by a 30 mg loading dose at the time of PCI had an increased risk of non-CABG peri-procedural bleeding and no additional benefit compared to patients receiving a 60 mg loading dose at the time of PCI (see sections 4.2 and 4.4).
V kliničnem preskušanju bolnikov z NSTEMI (študija ACCOAST), v kateri je bila za bolnike predvidena koronarna angiografija v obdobju 2 do 48 ur po randomizaciji, so bolniki, ki so prejeli 30- mg polnilni odmerek v povprečju 4 ure pred koronarno angiografijo, ki mu je sledil 30-mg polnilni odmerek v času perkutane koronarne intervencije, imeli povečano tveganje za krvavitev ob postopku, ki ni bila povezana s CABG in nobenih dodatnih koristi v primerjavi z bolniki, ki so prejeli 60-mg polnilni odmerek v času perkutane koronarne intervencije (glejte poglavji 4.2 in 4.4).
In a clinical study of NSTEMI patients (the ACCOAST study), where patients were scheduled to undergo coronary angiography within 2 to 48 hours after randomization, patients given a 30 mg loading dose on average 4 hours prior to coronary angiography followed by a 30 mg loading dose at the time of PCI had an increased risk of non-CABG peri-procedural bleeding and no additional benefit compared to patients receiving a 60 mg loading dose at the time of PCI (see sections 4.2 and 4.4).
V kliničnem preskušanju bolnikov z NSTEMI (študija ACCOAST), v kateri je bila za bolnike predvidena koronarna angiografija v obdobju 2 do 48 ur po randomizaciji, so bolniki, ki so prejeli 30- mg polnilni odmerek v povprečju 4 ure pred koronarno angiografijo, ki mu je sledil 30-mg polnilni odmerek v času perkutane koronarne intervencije, imeli povečano tveganje za krvavitev ob postopku, ki ni bila povezana s CABG, in nobenih dodatnih koristi v primerjavi z bolniki, ki so prejeli 60-mg polnilni odmerek v času perkutane koronarne intervencije (glejte poglavji 4.2 in 4.4).
In a clinical study of patients with Crohn’s disease (SONIC), infusion-related reactions occurred in 16.6% (27/163) of patients receiving infliximab monotherapy, 5% (9/179) of patients receiving infliximab in combination with AZA, and 5.6% (9/161) of patients receiving AZA monotherapy.
V klinični študiji pri bolnikih s Crohnovo boleznijo (SONIC) so se z infuzijo povezane reakcije pojavile pri 16,6 % (27/163) bolnikov, ki so prejemali infliksimab v monoterapiji, pri 5 % (9/179) bolnikov, ki so prejemali infliksimab v kombinaciji z AZA, in pri 5,6 % (9/161) bolnikov, ki so prejemali AZA v monoterapiji.
In a clinical study of patients with OIC, a daily dose of 50 mg was associated with an increased incidence of intolerable gastrointestinal effects (primarily abdominal pain).
V klinični študiji bolnikov z OIC, je bil dnevni odmerek 50 mg povezan z večjo incidenco nevzdržnih učinkov na prebavilih (predvsem bolečin v trebuhu).
In a clinical study of PTPs with haemophilia A (factor VIII:C ≤ 2%) undergoing major surgery, 1 inhibitor was observed in 30 patients who received treatment with ReFacto AF.
V klinični študiji pri PTP s hemofilijo A (faktor VIII:C ≤ 2%), ki so prestali večjo operacijo, so pri 30 bolnikih, ki so se zdravili z zdravilom ReFacto AF, ugotovili 1 inhibitor.
In a clinical study of subjects with mild, moderate, severe or end stage (dialysis-dependent) renal insufficiency, anidulafungin pharmacokinetics were similar to those observed in subjects with normal renal function.
V klinični študiji preiskovancev z blago, zmerno, hudo ali končno (od dialize odvisno) insuficienco ledvic je bila farmakokinetika anidulafungina podobna kot pri preiskovancih z normalnim delovanjem ledvic.
In a clinical study on pharmacokinetics of fosamprenavir in paediatric patients, eight subjects 12 to 18 years of age received the standard fosamprenavir adult tablet dose of 700 mg twice daily (with ritonavir 100 mg twice daily).
V klinični študiji o farmakokinetiki fosamprenavirja pri pediatričnih bolnikih, je 8 oseb, starih od 12 do 18 let, prejemalo standardni odmerek fosamprenavirja za odrasle v obliki 700 mg tablet dvakrat na dan (z ritonavirjem 100 mg dvakrat na dan).
In a clinical study performed in non-diabetic subjects covering a wide range of renal function (CrCl >80 ml/min, 30-50 ml/min, <30 ml/min), the rapid-acting properties of insulin glulisine were generally maintained.
V klinični študiji pri nediabetičnih preiskovancih z zelo različnim delovanjem ledvic (očistek kreatinina > 80 ml/min, 30–50 ml/min, < 30 ml/min) se je hitro delovanje insulina glulisin praviloma ohranilo.
In a clinical study that evaluated reactogenicity in children 3 to 5 and 6 to 9 years of age who received a single half adult (i.e.
V klinični študiji, s katero so ocenili reaktogenost pri otrocih, starih od 3 do 5 in od 6 do 9 let, ki so dobili en polovični odmerek (tj.
In a clinical study that evaluated reactogenicity in children aged 6 to 35 months who received two half adult (i.e.
V klinični študiji, s katero so ocenili reaktogenost pri otrocih, starih od 6 do 35 mesecev, ki so dobili dva polovična (tj.
In a clinical study the 7.5 µg dose of Celvapan (H1N1)v was administered to adults aged 18 to 59 years (N = 101) and older people over 60 years of age (N = 101).
V klinični študiji so odmerek 7,5 µg cepiva Celvapan (H1N1)v dajali odraslim osebam, starim od 18 do 59 let (N= 101) in starostnikom, starejšim od 60 let (N=101).
In a clinical study the frequency and type of side effects after the first and second injection were basically similar to that seen in the adult and older population using Celvapan.
V klinični študiji so bile pogostnosti in vrste neželenih učinkov po prvem in drugem odmerku cepiva v osnovi podobne kot pri odraslih in starostnikih, ki so prejeli cepivo Celvapan.
In a clinical study where ritonavir 100 mg capsules bid were co- administered with 50 µg intranasal fluticasone propionate (4 times daily) for 7 days in healthy subjects, the fluticasone propionate plasma levels increased significantly, whereas the intrinsic cortisol levels decreased by approximately 86% (90% confidence interval 82-89%).
V kliničnem preskušanju, v katerem so kapsule ritonavirja po 100 mg, 2- krat na dan, dajali sočasno s 50 μg intranazalnega flutikazon propionata (4-krat na dan) 7 dni zdravim osebam, so se ravni flutikazon propionata v plazmi pomembno povečale, medtem ko so se ravni intrinzičnega kortizola zmanjšale za približno 86
In a clinical study where ritonavir 100 mg capsules bid were co- administered with 50 µg intranasal fluticasone propionate (4 times daily) for 7 days in healthy subjects, the fluticasone propionate plasma levels increased significantly, whereas the intrinsic cortisol levels decreased by approximately 86% (90% confidence interval 82-89%).
V kliničnem preskušanju, v katerem so kapsule ritonavirja po 100 mg, 2- krat na dan, dajali sočasno s 50 μg intranazalnega flutikazon propionata (4-krat na dan) 7 dni zdravim osebam, so se ravni flutikazon propionata v plazmi pomembno povečale, medtem ko so se ravni intrinzičnega kortizola zmanjšale za približno 86% (90-odstotni interval zaupanja 82– 89%).
In a clinical study where ritonavir 100 mg capsules twice daily were co-administered with 50 g intranasal fluticasone propionate (4 times daily) for 7 days in healthy subjects, fluticasone propionate plasma concentrations increased significantly, whereas the intrinsic cortisol levels decreased by approximately 86% (90% CI 82-89%).
V kliničnem preskušanju, v kateri so pri zdravih prostovoljcih 7 dni sočasno uporabljali 100 mg ritonavirja v kapsulah dvakrat na dan s 50 µg flutikazonpropionata (štirikrat na dan intranazalno), so se plazemske koncentracije flutikazonapomembno zvečale, medtem, ko so se intrinzične koncentracije kortizola zmanjšale za približno 86% (90% interval zaupanja 82%-89%).
In a clinical study with ReFacto AF in previously treated patients (PTPs), the incidence of factor VIII inhibitors was the primary safety endpoint.
V klinični študiji z zdravilom ReFacto AF pri predhodno zdravljenih bolnikih (previously treated patients - PTP) je bila pogostnost inhibitorjev faktorja VIII primarni varnostni opazovani dogodek.
In a clinical study with ReFacto in PTPs, 1 inhibitor was observed in 113 patients.
V klinični študiji z zdravilom ReFacto pri PTP so pri 113 bolnikih ugotovili 1 primer inhibitorja.
In a clinical study, 100 infants with HIV infection were administered Rotarix or placebo.
V klinični študiji je 100 dojenčkov, okuženih s HIV, dobilo cepivo Rotarix ali placebo.
In a clinical study, a case of fatal autoimmune hepatitis occurred in a patient re-initiating treatment with 300 mg of daclizumab after a planned 6 month treatment interruption period.
V klinični študiji se je zgodil smrtni primer avtoimunega hepatitisa pri bolniku, ki se je ponovno začel zdraviti s 300 mg daklizumaba po načrtovanem 6-mesečnem prekinitvenem obdobju.
In a clinical study, adults 60 years of age or older received a second dose of ZOSTAVAX 42 days following the initial dose (see section 5.1).
V klinični študiji so odrasli, stari 60 let ali več, prejeli drugi odmerek cepiva ZOSTAVAX 42 dni po prvem odmerku (glejte poglavje 5.1).
In a clinical study, children 3 to 9 years of age have received either two adult (0.5 ml) or two half adult (0.25 ml) doses of a similar vaccine containing A/Vietnam/1194/2004.
V klinični študiji so otrokom, starim od 3 do 9 let, dali dvakrat bodisi odmerek za odrasle (0,5 ml) bodisi polovični odmerek za odrasle (0,25 ml) podobnega cepiva, ki je vsebovalo sev A/Vietnam/1194/2004.
In a clinical study, children 3 to 9 years of age have received either two adult (0.5 ml) or two half adult (0.25 ml) doses.
V klinični študiji so otrokom, starim od 3 do 9 let, dali dvakrat bodisi odmerek za odrasle (0,5 ml) bodisi polovični odmerek za odrasle (0,25 ml).
In a clinical study, dexmedetomidine contributed to postoperative analgesia for 0.5 – 4 hours.
V klinični študiji je deksmedetomidin prispeval k pooperativni analgeziji, ki je trajala 0,5–4 ure.
In a clinical study, the presence of hypoalbuminaemia was associated with an increased risk of prolongation of the QTc interval in delamanid treated patients.
V klinični študiji je bila prisotnost hipoalbuminemije povezana z večjim tveganjem podaljšanja intervala QTc pri bolnikih, zdravljenih z delamanidom.
In a clinical trial 131 adults and 123 elderly were exposed to two doses of the 7.5 µg Focetria.
V kliničnem preskušanju se je cepilo 131 odraslih in 123 starejših oseb z dvema odmerkoma 7,5 µg cepiva Focetria.
In a clinical trial 51 children and adolescents aged 9 to 17 years and 51 children aged 3 to 8 years were administered the 7.5 µg dose of Celvapan (H1N1)v.
V kliničnem preskušanju so 51 otrokom in mladostnikom, starim od 9 do 17 let, ter 51 otrokom, starim od 3 do 8 let, dali odmerek cepiva Celvapan (H1N1)v 7,5 µg.